Literature DB >> 15671025

A transmembrane form of the prion protein is localized in the Golgi apparatus of neurons.

Richard S Stewart1, David A Harris.   

Abstract

(Ctm)PrP is a transmembrane version of the prion protein that has been proposed to be a neurotoxic intermediate underlying prion-induced pathogenesis. In previous studies, we found that PrP molecules carrying mutations in the N-terminal signal peptide (L9R) and the transmembrane domain (3AV) were synthesized exclusively in the (Ctm)PrP form in transfected cell lines. To characterize the properties of (Ctm)PrP in a neuronal setting, we have utilized cerebellar granule neurons cultured from Tg(L9R-3AV) mice that developed a fatal neurodegenerative illness. We found that about half of the L9R-3AV PrP synthesized in these neurons represents (Ctm)PrP, with the rest being (Sec)PrP, the glycolipid anchored form that does not span the membrane. Both forms contained an uncleaved signal peptide, and they are differentially glycosylated. (Sec)PrP was localized on the surface of neuronal processes. Most surprisingly, (Ctm)PrP was concentrated in the Golgi apparatus, rather in the endoplasmic reticulum as it is in transfected cell lines. Our study is the first to analyze the properties of (Ctm)PrP in a neuronal context, and our results suggest new hypotheses about how this form may exert its neurotoxic effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671025     DOI: 10.1074/jbc.M412298200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Cellular prion protein is present in mitochondria of healthy mice.

Authors:  Robert Faris; Roger A Moore; Anne Ward; Brent Race; David W Dorward; Jason R Hollister; Elizabeth R Fischer; Suzette A Priola
Journal:  Sci Rep       Date:  2017-02-02       Impact factor: 4.379

2.  Cell-specific metabolism and pathogenesis of transmembrane prion protein.

Authors:  Yaping Gu; Xiu Luo; Subhabrata Basu; Hisashi Fujioka; Neena Singh
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

Review 3.  Lysosomal Quality Control in Prion Diseases.

Authors:  Priyanka Majumder; Oishee Chakrabarti
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

4.  Failure of prion protein oxidative folding guides the formation of toxic transmembrane forms.

Authors:  Silvia Lisa; Beatriz Domingo; Javier Martínez; Sabine Gilch; Juan F Llopis; Hermann M Schätzl; María Gasset
Journal:  J Biol Chem       Date:  2012-09-06       Impact factor: 5.157

5.  Prions disturb post-Golgi trafficking of membrane proteins.

Authors:  Keiji Uchiyama; Naomi Muramatsu; Masashi Yano; Takeshi Usui; Hironori Miyata; Suehiro Sakaguchi
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

6.  Neurodegenerative illness in transgenic mice expressing a transmembrane form of the prion protein.

Authors:  Richard S Stewart; Pedro Piccardo; Bernardino Ghetti; David A Harris
Journal:  J Neurosci       Date:  2005-03-30       Impact factor: 6.167

Review 7.  Prion protein biosynthesis and its emerging role in neurodegeneration.

Authors:  Oishee Chakrabarti; Aarthi Ashok; Ramanujan S Hegde
Journal:  Trends Biochem Sci       Date:  2009-05-15       Impact factor: 13.807

8.  Signal sequence insufficiency contributes to neurodegeneration caused by transmembrane prion protein.

Authors:  Neena S Rane; Oishee Chakrabarti; Lionel Feigenbaum; Ramanujan S Hegde
Journal:  J Cell Biol       Date:  2010-02-15       Impact factor: 10.539

9.  Polar substitutions in helix 3 of the prion protein produce transmembrane isoforms that disturb vesicle trafficking.

Authors:  Jonatan Sanchez-Garcia; Daniela Arbelaez; Kurt Jensen; Diego E Rincon-Limas; Pedro Fernandez-Funez
Journal:  Hum Mol Genet       Date:  2013-06-13       Impact factor: 6.150

Review 10.  Prion neurotoxicity: insights from prion protein mutants.

Authors:  Isaac H Solomon; Jessie A Schepker; David A Harris
Journal:  Curr Issues Mol Biol       Date:  2009-09-18       Impact factor: 2.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.